10.4 BOLT

Summary

Study investigators had noted several small, uncontrolled studies evaluating bevacizumab found a purported beneficial effect in the treatment of DME. As such, they undertook a direct comparison (open-label) study.

Read

Module 10.4.pdf
pdf, 879.8 KB

Quiz Module 10.4

Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account

1. Which of the following is true of the BOLT study?

a. Patients in the bevacizumab arm received more treatments than those in the laser treatment arm and saw a smaller change in central retinal thickness at two years.

b. Patients in the bevacizumab arm received less treatments than those in the laser treatment arm and saw a smaller change in central retinal thickness at two years.

c. Patients in the bevacizumab arm received more treatments than those in the laser treatment arm and saw a greater change in central retinal thickness at two years.

d. Patients in the bevacizumab arm received less treatments than those in the laser treatment arm and saw a greater change in central retinal thickness at two years.

2. The BOLT Study showed that:

a. Bevacizumab WAS beneficial in patients with DME who had persistent macular edema

b. Bevacizumab WAS NOT beneficial in patients with DME who had persistent macular edema

c. Aflibercept WAS beneficial in patients with DME who had persistent macular edema

d. Aflibercept WAS NOT beneficial in patients with DME who had persistent macular edema

Beta version!

10.4 BOLT

Summary

Read

Quiz Module 10.4